Review article

Antiresorptive agents in the treatment of osteoporosis

Srđan Novak ; Department for Rheumatology and Clinical Immunology, Clinic for Internal Medicine, Clinical Hospital Centre Rijeka, Rijeka, Croatia

Abstract

The aim of drug treatment of osteoporosis is the balance between activity of osteoblasts and osteoclasts with augmentation of mineral bone density and decrease of fracture risk. Antiresorptive agents depress osteoclasts and diminish resorption of bone. They include bisphosphonates, selective estrogen receptor modulators (SERMs), denosumab, while hormone replacement therapy and calcitonin are mostly abandoned. By binding to hydroxyapatite crystals of bone surface bisphosphonates inhibit the resorption of bone and prevent vertebral and non-vertebral fractures. Denosumab is a monoclonal antibody which by hindering interaction between RANKL and RANK inhibits osteoclastogenesis and diminishes bone resorption in cortical and trabecular bones, thus significantly lessening fracture risk.

Keywords

antiresorptive agents; bisphosphonates; denosumab; treatment

Hrčak ID:

137904

URI

https://hrcak.srce.hr/137904

Publication date:

23.10.2014.

Article data in other languages: croatian

Visits: 2.454 *